SEK83.6 -1.0 -1.2%
Last Trade - 5:00pm
| Market Cap | £362.6m |
| Enterprise Value | £348.6m |
| Revenue | £408k |
| Position in Universe | 560th / 1829 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 62.8 | 55.6 | 48.0 | 35.6 | 12.1 | 4.78 | 35.0 | 116 | -40.3% | ||
| -98.5 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | April 7, 2017 |
| No. of Shareholders: | 9,730 |
| No. of Employees: | 12 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 50,160,388 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Vastertorpsvagen 135, HAGERSTEN, 129 44, Sweden |
| Web | http://intervacc.se/ |
| Phone | +46 8 12010600 |
| Contact | () |
| Auditors | Ohrlings PricewaterhouseCoopers AB |
As of 5:00pm, shares in Intervacc AB are trading at SEK83.6, giving the company a market capitalisation of £362.6m. This share price information is delayed by 15 minutes.
Shares in Intervacc AB are currently trading at SEK83.6 and the price has moved by 0.297k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Intervacc AB price has moved by 0.208k% over the past year.
Of the analysts with advisory recommendations for Intervacc AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Intervacc AB is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Intervacc AB is scheduled to issue upcoming financial results on the following dates:
Intervacc AB does not currently pay a dividend.
Intervacc AB does not currently pay a dividend.
Intervacc AB does not currently pay a dividend.
To buy shares in Intervacc AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Intervacc AB are currently trading at SEK83.6, giving the company a market capitalisation of £362.6m.
Here are the trading details for Intervacc AB:
Based on an overall assessment of its quality, value and momentum, Intervacc AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Intervacc AB are currently priced at SEK83.6. At that level they are trading at 30.02% discount to the analyst consensus target price of 0.00.
Analysts covering Intervacc AB currently have a consensus Earnings Per Share (EPS) forecast of -0.48 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intervacc AB. Over the past six months, the relative strength of its shares against the market has been 39.98%. At the current price of SEK83.6, shares in Intervacc AB are trading at 66.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Intervacc AB.
Intervacc AB's management team is headed by:
Here are the top five shareholders of Intervacc AB based on the size of their shareholding:
